论文部分内容阅读
急性髓细胞白血病（ＡＭＬ）－Ｍ＿（２ｂ）患者约９０％有ｔ（８；２１）。已经证明它导致ＡＭＬ＿１－ＥＴＯ融合基因。我们应用逆转录酶／聚合酶链反应（ＲＴ／ＰＣＲ）检测了２２例ＡＭＬ＿１－Ｍ＿（２ｂ）其中ｔ（８；２１）阳性１６例，阴性２例，不能确定有无ｔ（８；２１）的４例，发现全部２２例患者均可检出ＡＭＬ＿１－ＥＴＯ融合基因转录本。同时在５例ｔ（８；２１）阴性的ＡＭＬ中，包括Ｍ＿（２ａ）２例，Ｍ＿４２例，Ｍ＿３１例，均未检出上述融合基因转录本。我们的初步结果提示ＡＭＬ＿１－ＥＴＯ融合基因可以作为ＡＭＬ－Ｍ＿（２ｂ）的基因标志。
About 90% of patients with acute myeloid leukemia (AML)-M_(2b) have t(8;21). It has been shown to cause the AML_1-ETO fusion gene. We used reverse transcriptase/polymerase chain reaction (RT/PCR) to detect 22 cases of AML_1-M_(2b), of which t(8;21) was positive in 16 cases and negative in 2 cases. We could not determine whether there was no t(8;21). In 4 cases, AML 1 -ETO fusion gene transcripts were detected in all 22 patients. At the same time, in 5 cases of t(8;21) negative AML, including M_(2a) in 2 cases, M_42 cases, and M_31 cases, none of the fusion gene transcripts were detected. Our preliminary results suggest that AML_1-ETO fusion gene can be used as a gene marker of AML-M_(2b).